Esperion Therapeutics, Inc. 4
4 · Esperion Therapeutics, Inc. · Filed Apr 27, 2015
Insider Transaction Report
Form 4
Aisling Capital II LP
10% Owner
Transactions
- Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.)
Footnotes (1)
- [F1]The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.